Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Charles Elliott Sigal is Director at Alnylam Pharmaceuticals. OQRO lists 1 transaction filed with the SEC under this name, the latest on Nov 12, 2026, each linked to the official Form 4.
Director
Disclosures on record
1
Companies involved
1
1 purchase disclosed. $1,000 placed after each of the 1 purchases disclosed since 2025-11-14 would be worth $1K today ($1K put in); the same in the S&P 500 (SPY): $1K.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 82 ranked insiders is −5.5 pts (median, against the S&P 500).
Equal weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
Nov 10, 2026Bought~$244Kdisclosed Nov 12
DetailsOfficial recordAs of the latest filing on , Charles Elliott Sigal reported holding 3,600 shares of Alnylam Pharmaceuticals (ALNY), worth about $594K at the last close of $165 (Nov 13, 2026), held through a trust. In the last 12 months, Charles Elliott Sigal bought $244K in 1 open-market purchase.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Alnylam Pharmaceuticals ALNY | 3,600 | 3,600 trust | $165 | $594K | Nov 10, 2026 |
Is this Charles Elliott Sigal’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Charles Elliott Sigal bought shares on the open market in 2023 and 2026 across 2 companies.
Charles Elliott Sigal reported 5 open-market purchases and 0 sales since 2023; purchases in 2 different years, most recently 2026.
| Year | Bought | Sold |
|---|---|---|
| 2026 | $244K1×1 trade | — |
| 2023 | $246K4×4 trades | — |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 10, 2026, Charles Elliott Sigal reported holding 3,600 shares of Alnylam Pharmaceuticals (ALNY), held indirectly. At the last close of $165 on Nov 13, 2026, that is about $594K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Charles Elliott Sigal reported 1 open-market purchase worth $244K, and no open-market sale. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Charles Elliott Sigal bought shares on the open market in 2023 and 2026 across 2 companies.
In SEC filings since 2023: the latest open-market purchase is from 2026; no open-market sale is on record.
2 companies: Alnylam Pharmaceuticals (ALNY, 2026), Vir Biotechnology, Inc. (VIR, 2023).
Charles Elliott Sigal reported 4 open-market purchases and 0 sales here, 2023.
Charles Elliott Sigal reported 1 open-market purchase and 0 sales here, 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
